Interpace Biosciences (NASDAQ:IDXG) announced its quarterly earnings data on Tuesday. The business services provider reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by ($0.37), Yahoo Finance reports. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%.
IDXG opened at $4.19 on Friday. The firm has a 50 day moving average price of $3.56 and a 200 day moving average price of $3.88. The company has a market cap of $16.94 million, a PE ratio of -0.49 and a beta of 1.23. Interpace Biosciences has a 1 year low of $2.57 and a 1 year high of $11.00. The company has a debt-to-equity ratio of 2.01, a quick ratio of 1.62 and a current ratio of 1.62.
Several research analysts have recently weighed in on the stock. Alliance Global Partners cut their price objective on shares of Interpace Biosciences from $9.25 to $7.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. Zacks Investment Research upgraded shares of Interpace Biosciences from a “sell” rating to a “hold” rating in a report on Monday, November 30th. Finally, HC Wainwright cut their price objective on shares of Interpace Biosciences from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $9.67.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Read More: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.